Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Liabilities and Shareholders Equity (2018 - 2025)

Historic Liabilities and Shareholders Equity for Whitehawk Therapeutics (WHWK) over the last 8 years, with Q3 2025 value amounting to $167.0 million.

  • Whitehawk Therapeutics' Liabilities and Shareholders Equity rose 9489.02% to $167.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $652.2 million, marking a year-over-year increase of 5137.86%. This contributed to the annual value of $70.3 million for FY2024, which is 4689.82% down from last year.
  • As of Q3 2025, Whitehawk Therapeutics' Liabilities and Shareholders Equity stood at $167.0 million, which was up 9489.02% from $180.8 million recorded in Q2 2025.
  • Whitehawk Therapeutics' 5-year Liabilities and Shareholders Equity high stood at $234.0 million for Q1 2025, and its period low was $37.4 million during Q2 2021.
  • In the last 5 years, Whitehawk Therapeutics' Liabilities and Shareholders Equity had a median value of $142.3 million in 2022 and averaged $136.8 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first skyrocketed by 24575.87% in 2022, then crashed by 4689.82% in 2024.
  • Over the past 5 years, Whitehawk Therapeutics' Liabilities and Shareholders Equity (Quarter) stood at $157.9 million in 2021, then rose by 16.67% to $184.2 million in 2022, then dropped by 28.12% to $132.4 million in 2023, then plummeted by 46.9% to $70.3 million in 2024, then soared by 137.51% to $167.0 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $167.0 million for Q3 2025, versus $180.8 million for Q2 2025 and $234.0 million for Q1 2025.